ÂÜÀòÂÒÂ×

Alan Fuhrman is the current director at SpringWorks Therapeutics. Prior to this, they held positions at Esperion Therapeutics, Checkmate Pharmaceuticals, and Mirna Therapeutics. Fuhrman has also served on the board of Loxo Oncology.

Fuhrman began their career in the pharmaceutical industry at Checkmate Pharmaceuticals in June 2019. Alan served as the Board Member/Interim CEO/Audit Chair/Compensation Committee before the company was acquired by Regeneron in May 2022.

In September 2015, Fuhrman joined Mirna Therapeutics as the CFO. During their time at Mirna, the company announced a merger with Synlogic Therapeutics in May of 2017. However, in September of 2016, the Phase 1 trial for MRX34 was voluntarily halted due to safety issues. The FDA put the IND for MRX34 on full clinical hold soon after. Fuhrman left Mirna in August 2017.

From January 2015 to February 2019, Fuhrman served on the board of Loxo Oncology as the Board Member/Audit Chair/Compensation Committee.

Fuhrman’s experience in the pharmaceutical industry and their roles on various boards make him well-qualified for their current position as the director at SpringWorks Therapeutics.

Alan Fuhrman has a BS in Agriculture from Montana State University-Bozeman and a BS in Business Administration from Montana State University-Bozeman. Alan has a background in Economics and Accounting.